Using advanced math and AI to improve drug discovery and understand COVID-19 variants
Discovery-Driven Mathematics and Artificial Intelligence for Biosciences and Drug Discovery
This study is exploring how advanced math and artificial intelligence can help find new drugs and understand how COVID-19 variants change, with the goal of creating better treatments and prevention methods for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Michigan State University NIH-funded |
| Lab location | 1 site (East Lansing, United States) |
| Project ID | NIH-10919754 on NIH RePORTER |
What this research studies
This research focuses on leveraging advanced mathematics and artificial intelligence to enhance drug discovery processes and better understand the evolution of COVID-19 variants. By employing techniques such as algebraic topology and differential geometry, the team aims to create predictive models for emerging viral variants and their potential impacts. The research also seeks to develop an AI platform that can assist in drug design and pandemic forecasting, addressing significant challenges in the biosciences field. Patients may benefit from improved treatments and preventive measures against COVID-19 variants as a result of this innovative approach.
Who could benefit from this research
Good fit: Ideal candidates for participation or benefit from this research include individuals affected by COVID-19 or those at risk of infection, particularly in the context of emerging variants.
Not a fit: Patients who are not affected by COVID-19 or its variants may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments and preventive strategies for COVID-19 variants.
How similar studies have performed: Other research has shown success in using AI and mathematical models for drug discovery and understanding viral evolution, indicating that this approach has potential.
Where this research is happening
East Lansing, United States
- Michigan State University — East Lansing, United States (Active)
Researchers
- Principal investigator: Wei, Guowei — Michigan State University
- Study coordinator: Wei, Guowei
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.